Different metastatic sites are often accompanied by different types of ctDNA mutations: TP53 mutations are more common in intrahepatic metastasis; KRAS mutations are common in lung metastasis, indicating enhanced tumor invasiveness; peritoneal dissemination is associated with inactivation mutations of CTNNB1 and BAP1, suggesting that drug resistance may increase (Amato et al., 2019). The gene discussed is KRAS; the disease is neoplasm.